Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: A retrospective cohort study in Catalonia, Spain

British Journal of Cancer

Volumn 107, Issue 8, 2012, Pages 1249-1256

  Font, R ^a,b   Espinas, J A ^a   Gil Gil, M ^c   Barnadas, A ^d   Ojeda, B ^d   Tusquets, I ^e   Segui, M A ^f   Margeli M ^g   Arcusa, A ^h   Prat, A ⁱ   Garcia, M ^c   Borras, J M ^a,b  

^a Catalonian Regional Authority   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f Parc Tauli Health Corporation   (Spain)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^h Terrassa Health Consortium ^*  (Spain)

ⁱ Department of Health   (Spain)

Author keywords

Adherence; Early breast cancer; Endocrine therapy; Persistence

Indexed keywords

ANASTROZOLE; EXEMESTANE; HORMONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; EARLY CANCER; FEMALE; FOLLOW UP; HOSPITAL; HUMAN; KAPPA STATISTICS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; RISK FACTOR; SELF REPORT; SPAIN; TELEPHONE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SELF REPORT; SPAIN;

EID: 84867397617     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.389     Document Type: Article

References (41)

1. Andersson K, Melander A, Svensson C, Lind O, Nilsson JL (2005) Repeat prescriptions: refill adherence in relation to patient and prescriber characteristics, reimbursement level and type of medication. Eur J Public Health 15: 621-626 (Pubitemid 41790247)
2. Atkins L, Fallowfield L (2006) Intentional and non-intentional nonadherence to medication amongst breast cancer patients. Eur J Cancer 42: 2271-2276 (Pubitemid 44307611)
3. Banning M (2012) Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review. Eur J Cancer Care 21: 10-19
4. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ (2007) Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 109: 832-839 (Pubitemid 46333524)
5. Bell K (2009) 'If it almost kills you that means it's working!' Cultural models of chemotherapy expressed in a cancer support group. Soc Sci Med 68: 169-176
6. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353: 1784-1792 (Pubitemid 41549890)
7. Borras JM, Espinas JA, Ferro T, Ribes J, Clèries R, Aliste L, Corral J, Escribà JM, Esteban L, Font R, Gálvez J, Manchon P, Melià A, Pareja L, Prades JLl, Roca L, Sanz X (2009) Cancer strategy in Catalonia, Spain. Clin Transl Oncol 11: 1-30
8. Borras JM, Sanchez-Hernandez A, Navarro M, Martinez M, Mendez E, Ponton JL, Espinas JA, Germa JR (2001) Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial. BMJ 322: 826
9. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11: 44-47 (Pubitemid 351160875)
10. Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, Hatfield A, Cortes J (2007) Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 25: 481-496 (Pubitemid 46849189)
11. DiMatteo R (2004) Variations in patient adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 42: 200-209
12. Early Breast Cancer Trialist' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717
13. Escalada P, Griffiths P (2006) Do people with cancer comply with oral chemotherapy treatments? Br J Community Nurs 11: 532-536
14. Fallowfield L, Atkins L, Catt S, Cox A, Coxon C, Langridge C, Morris R, Price M (2006) Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 17: 205-210 (Pubitemid 43160107)
15. Fisher B, Dignam J, Bryant J, Wolmark N (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor positive tumors. JNCI 88: 1529-1542 (Pubitemid 26374506)
16. Grunfeld EA, Hunter MS, Sikka P, Mittal S (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59: 97-102 (Pubitemid 41399883)
17. Haynes RB, Sackett DL, Taylor DW, Roberts RS, Johnson AL (1977) Manipulation of the therapeutic regimen to improve compliance: conceptions and misconceptions. Clin Pharmacol Ther 22: 125-130 (Pubitemid 8168323)
18. Herk-Sukel MP, van de Poll-Franse LV, Voogd AC, Nieuwenhuijzen GA, Coebergh JW, Herings RM (2010) Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat 122: 843-851
19. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Lin GS, Miles S, Neugut AI (2010a) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28: 4120-4128
20. Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI (2010b) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2): 529-537
21. Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33: 159-174 (Pubitemid 8054849)
22. Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99: 215-220 (Pubitemid 44268270)
23. Lebovits AH, Strain JJ, Schleifer SJ, Tanaka JS, Bhardwaj S, Messe MR (1990) Patient noncompliance with self-administered chemotherapy. Cancer 65: 17-22 (Pubitemid 20026803)
24. Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15: 110-115 (Pubitemid 27021524)
25. Manchon P, Borras JM, Ferro T, Espinas JA, Breast Cancer OncoGuia Group (2010) Breast Cancer OncoGuia. Clin Transl Oncol 12: 113-138
26. McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99: 1763-1768
27. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thurlimann B, Paridaens R, Smith I, Mauriac L, Forbes JF, Price KN, Regan MM, Gelber RD, Coates AS (2009) Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361: 766-776
28. Murthy V, Bharia G, Sarin R (2002) Tamoxifen non-compliance: does it matter? Lancet Oncol 3: 654 (Pubitemid 35314907)
29. Nilsson JL, Andersson K, Bergkvist A, Bjorkman I, Brismar A, Moen J (2006) Refill adherence to repeat prescriptions of cancer drugs to ambulatory patients. Eur J Cancer Care 15: 235-237 (Pubitemid 44050693)
30. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353: 487-497 (Pubitemid 41127293)
31. Partridge AH (2006) Non-adherence to endocrine therapy for breast cancer. Ann Oncol 17: 183-184 (Pubitemid 43160103)
32. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26: 556-562 (Pubitemid 351264348)
33. Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21: 602-606 (Pubitemid 46621892)
34. Rudd P (1979) In search of the gold standard for compliance measurement. Arch Intern Med 139: 627-628 (Pubitemid 10135247)
35. Ruddy K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59: 56-66
36. Shi L, Liu J, Koleva Y, Fonseca V, Kalsekar A, Pawaskar M (2010) Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. Pharmacoeconomics 28: 1097-1107
37. Thompson AM, Dewar J, Fahey T, McCowan C (2007) Association of poor adherence to prescribed tamoxifen with risk of death from breast cancer. Society of Clinical Oncology Breast Cancer Symposium; San Francisco, California (abstract No. 130)
38. Verma S, Madarnas Y, Shedev S, Martin G, Bajcar J (2011) Patient adherence to aromatase inhibitor treatment in the adjuvant setting. Curr Oncol 11: S3-S9
39. Wang PS, Benner JS, Glynn RJ, Winkelmayer WC, Mogun H, Avorn J (2004) How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptions. Pharmacoepidemiol Drug Saf 13: 11-19 (Pubitemid 38159264)
40. Waterhouse DM, Calzone KA, Mele C, Brenner DE (1993) Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 11: 1189-1197 (Pubitemid 23163362)
41. Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U, Hadji P (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20: 431-436